KG
MLYS icon

Kilter Group’s Mineralys Therapeutics MLYS Stock Holding History

Kilter Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Hold
69
– – ﹤0.01% 1046
2026
Q1 		$1.87K Buy
+69
New +$2.02K ﹤0.01% 978

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kilter Group's MLYS Position: Q2 2026 in Review

Kilter Group held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 69 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Kilter Group first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.87K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Kilter Group held 69 shares of Mineralys Therapeutics worth $1.86K as of Q2 2026.
  • Kilter Group left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1046 holding.
  • Kilter Group first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Kilter Group's Mineralys Therapeutics position peaked at $1.87K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.